Zepbound 30% Price Cut to $299 Still Far Above Cheaper Overseas Options

Eli Lilly’s Zepbound vials pictured as the company cuts US cash prices, while overseas patients still pay significantly less. (PHOTO: LILLY.COM)

Eli Lilly has announced price reductions on its blockbuster weight-loss drug Zepbound, bringing the starting monthly dose to £226 ($299) for cash-paying American patients via LillyDirect.

While the pharmaceutical giant frames the move as a win for accessibility, the discounted rate—available only through single-dose vials—still exceeds prices for the same active ingredient (tirzepatide) in markets like India and Canada, though Japan £241($319) is now slightly higher than this new US cash price.